Ascletis Pharma (1672.HK) Earnings Analysis
Ascletis Pharma (1672.HK) next reports earnings on 2026-08-24, consensus EPS -0.23092 HKD. Last quarter (2026-03-31) it beat with EPS -0.31161 HKD vs -0.31161 HKD est (0%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -20.51.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1672.HK next report earnings?
| Next earnings date | 2026-08-24 |
|---|---|
| Consensus EPS estimate | -0.23092 HKD |
| Revenue estimate | 0.03B |
1672.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-31 | -0.31161 HKD | -0.31161 HKD | 0% | Beat |
| 2025-06-30 | -0.09997 HKD | -0.14245 HKD | +29.8% | Beat |
| 2024-08-30 | -0.13769 HKD | -0.12893 HKD | -6.8% | Miss |
Beat rate: 2/3 (67%) over reported quarters with consensus data.
1672.HK valuation and analyst view
| Trailing P/E | -20.51 |
|---|---|
| Trailing EPS | -0.36629 HKD |
| Price / book | 3.87 |
| Dividend yield | 0.00% |
| Market cap | 9.17B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Ascletis Pharma (1672.HK)'s next earnings date?
Ascletis Pharma is next scheduled to report on 2026-08-24, with a consensus EPS estimate of -0.23092 HKD and revenue estimate of 0.03B.
Did 1672.HK beat earnings last quarter?
In its 2026-03-31 report, 1672.HK posted EPS of -0.31161 HKD versus a -0.31161 HKD estimate — a beat of 0%.
What is 1672.HK's earnings track record?
Over the last 3 reported quarters with consensus data, 1672.HK beat estimates 2 times (67%).
What is 1672.HK's current P/E ratio and EPS?
1672.HK trades at a trailing P/E of -20.51 on trailing EPS of -0.3662893896131749 HKD.
What do analysts rate 1672.HK?
1672.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.